ClinicalTrials.gg
Active, not recruitingNCT06220201Updated Aug 3, 2026

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

A Phase 1 interventional study of CC-97540 and Fludarabine in Multiple Sclerosis and Myasthenia Gravis, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Active, not recruiting at 34 sites in 6 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Multiple Sclerosis by Bristol-Myers Squibb — 4 open to participants now, 7 under way, 1 of them phase 3. Multiple Sclerosis · Bristol-Myers Squibb.

Planned enrollment
8th of 12
120 · median 191
Started
2024
with 1 other
Phase 1
3 of 18
none open now
Registered
14th of 18
by date

Among the 18 studies in Multiple Sclerosis by Bristol-Myers Squibb, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 in phase 1, and was the 14th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

4 of the 18 studies in Multiple Sclerosis by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Multiple Sclerosis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).

03

Conditions studied

  • Multiple Sclerosis
  • Myasthenia Gravis

Keywords

  • CC-97540
  • CAR T
  • CART
  • NEX T
  • NEXT
  • BMS-986353
  • RMS
  • PMS
  • Multiple sclerosis
  • RRMS
  • aSPMS
  • PPMS
  • iSPMS
  • MG
  • gMG
  • refractory myasthenia gravis
  • general myasthenia gravis
  • CD19
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Relapsing forms of Multiple Sclerosis (RMS) - Cohort 1.

i) Participants must have an Expanded Disability Status Scale (EDSS) of ≥ 3.0 and ≤ 5.5.

ii) Participants must have a diagnosis of Multiple Sclerosis (MS) with MS or conversion to active secondary progressive multiple sclerosis (aSPMS), and worsening of disease within 12 months prior to Screening and while on treatment with a high-efficacy DMT for at least 6 months.

- Progressive forms of MS - Cohort 2.

i) Participants must have an EDSS ≥ 3.0 and ≤ 6.0.

ii) Participants must have a diagnosis of primary progressive multiple sclerosis (PPMS) that is treatment-resistant or diagnosis of inactive secondary progressive multiple sclerosis (iSPMS).

- Myasthenia Gravis - Cohort 3

i)MGFA classification of II-IV at screening

ii) Documentation of autoantibodies against AChR or MuSK (historical or at Screening)

iii) Refractory disease defined as disease activity on at least 2 , including , NSIs, or biologics.

iv) Has had thymectomy, only if indicated according to current guidelines.

Exclusion criteria

Exclusion Criteria

  • Cohorts 1 and 2: Participants that cannot complete the 9-Hole Peg Test (9-HPT) in at least 1 hand in \<240 seconds unless extenuating medical conditions unrelated to MS prohibit this.
  • Participants that cannot perform a Timed 25-Foot Walk Test (T25FWT) in \< 150 seconds.
  • Presence of other confounding peripheral nervous system disorders or other disorders that may impact muscle strength (eg, myositis) or cause weakness, stroke, chronic inflammatory demyelinating polyradiculoneuropathy, Lambert-Eaton myasthenic syndrome.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Administration of CC-97540 (RMS arm)

    Drug: CC-97540 · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Administration of CC-97540 (PMS arm)

    Drug: CC-97540 · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Administration of CC-97540 (MG arm)

    Drug: CC-97540 · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to week 104

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to week 104

  3. Number of participants with adverse events of special interest (AESIs)

    Time frame: Up to week 104

  4. Number of participants with laboratory test result abnormalities

    Time frame: Up to week 104

  5. Number of participants with imaging abnormalities

    For Cohorts 1 and 2

    Time frame: Up to week 104

  6. Number of participants with dose-limiting toxicities (DLTs)

    Time frame: Up to week 104

  7. Recommended Phase 2 dose (RP2D) based on the incidence of DLTs that occur during the DLT evaluation period

    Time frame: Up to week 104

Secondary outcomes

  1. Number of participants meeting no evidence of disease activity (NEDA) criteria

    Time frame: Up to week 104

  2. Number of participants with confirmed disability progression per Expanded Disability Status Scale (EDSS)

    Time frame: Up to week 12

  3. Annualized relapse rate

    Time frame: Up to week 104

  4. Change from baseline in magnetic resonance imaging (MRI) metrics

    MRI metrics assessed are 1) number of gadolinium-enhancing T1 lesions and 2) total number of new or enlarging hyperintense T2-weigted lesions

    Time frame: Up to week 104

  5. Number of participants with disability improvement confirmed per EDSS

    Time frame: Up to week 12

  6. Maximum observed blood concentration (Cmax)

    Time frame: Up to week 104

  7. Time of maximum observed blood concentration (Tmax)

    Time frame: Up to week 104

  8. Area under the blood concentration-time curve from time zero to 28 days after dosing (AUC(0-28D))

    Time frame: Up to week 104

  9. Time to last measurable chimeric antigen receptor (CAR T) concentrations (Tlast)

    Time frame: Up to week 104

  10. Number of participants with at least 2 points improvement for at least 4 weeks in Myasthenia Gravis activities of daily living (MG-ADL) score

    For Cohort 3

    Time frame: Up to week 26

  11. Number of participants with at least 3 point improvement in Myasthenia Gravis composite (MG-C) score

    For Cohort 3

    Time frame: Up to week 26

  12. Number of participants with at least 3 point improvement in quantitative Myasthenia Gravis (QMG) score

    For Cohort 3

    Time frame: Up to week 26

07

Study locations

34 sites
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jul 2027, 39 months after the start.

Of 39 industry-sponsored phase 1 interventional studies under Multiple Sclerosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 32. This study's planned 39 months is above that.

Counting every sponsor, half of 92 studies reached it within 30 months; a quarter within 9 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
Jan 23, 2024
StartActual
Mar 28, 2024
Primary completionEst.
Jul 15, 2027
CompletionEst.
Jul 15, 2027
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06220201
Collaborators
Celgene Corporation
Responsible party
Sponsor
First posted
Jan 23, 2024
Start date
Mar 28, 2024
Primary completion
Jul 15, 2027 (estimated)
Completion
Jul 15, 2027 (estimated)
Last update
Aug 3, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zolacabtagene autoleucel

Start the discussion